Levosimendan: A New Therapeutic Option in the Treatment of Primary Graft Dysfunction After Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 28, Issue 5, 2009, Pages 501-504

  Weis, Florian ^a   Beiras Fernandez, Andres ^a   Kaczmarek, Ingo ^a   Sodian, Ralf ^a   Kur, Felix ^a   Weis, Marion ^a   Schmoeckel, Michael ^a   Reichart, Bruno ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CORTICOSTEROID; LEVOSIMENDAN; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PROSTACYCLIN; TACROLIMUS; VASOPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT DYSFUNCTION; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; INOTROPISM; MALE; PRIORITY JOURNAL;

ADULT; AGED; CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PYRIDAZINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67349145362     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.01.017     Document Type: Article

References (26)

1. Lima B., Rajagopal K., Petersen R.P., et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation 114 (2006) I27-I32
2. Marasco S.F., Esmore D.S., Richardson M., et al. Prolonged cardiac allograft ischemic time--no impact on long-term survival but at what cost?. Clin Transplant 21 (2007) 321-329
3. Aharinejad S., Schafer R., Krenn K., et al. Donor myocardial HIF-1alpha is an independent predictor of cardiac allograft dysfunction: a 7-year prospective, exploratory study. Am J Transplant 7 (2007) 2012-2019
4. Myburgh J.A. Catecholamines for shock: the quest for high-quality evidence. Crit Care Resusc 9 (2007) 352-356
5. Patel G.P., Gurka D.P., and Balk R.A. New treatment strategies for severe sepsis and septic shock. Curr OpinCrit Care 9 (2003) 390-396
6. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
7. Marasco S.F., Preovolos A., Lim K., and Salamonsen R.F. Thoracotomy in adults while on ECMO is associated with uncontrollable bleeding. Perfusion 22 (2007) 23-26
8. Marasco S.F., Esmore D.S., Negri J., et al. Early institution of mechanical support improves outcomes in primary cardiac allograft failure. J Heart Lung Transplant 24 (2005) 2037-2042
9. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297 (2007) 1883-1891
10. Russ M.A., Prondzinsky R., Christoph A., et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35 (2007) 2732-2739
11. Schulze-Neick I., Luther Y.C., Ewert P., Lehmkuhl H.B., Hetzer R., and Lange P.E. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation 78 (2004) 1237-1238
12. Beiras-Fernandez A., Weis F.C., Fuchs H., Meiser B.M., Reichart B., and Weis M. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery?. Transplantation 82 (2006) 1101-1103
13. Rodeheffer R.J., Naftel D.C., Stevenson L.W., et al. Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database Group. Circulation 94 (1996) 2883-2889
14. Young J.B., Hauptman P.J., Naftel D.C., et al. Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis. J Heart Lung Transplant 20 (2001) 212
15. Martikainen T.J., Tenhunen J.J., Giovannini I., Uusaro A., and Ruokonen E. Epinephrine induces tissue perfusion deficit in porcine endotoxin shock: evaluation by regional CO(2) content gradients and lactate-to-pyruvate ratios. Am J Physiol Gastrointest Liver Physiol 288 (2005) G586-G592
16. Sautner T., Wessely C., Riegler M., et al. Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock. Ann Surg 228 (1998) 239-248
17. Luchette F.A., Jenkins W.A., Friend L.A., Su C., Fischer J.E., and James J.H. Hypoxia is not the sole cause of lactate production during shock. J Trauma 52 (2002) 415-419
18. Luchette F.A., James J.H., and Fischer J.E. Does epinephrine explain hyperlactatemia in cardiogenic shock?. Crit Care Med 29 (2001) 1848
19. James J.H., Luchette F.A., McCarter F.D., and Fischer J.E. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 354 (1999) 505-508
20. Luckraz H., Goddard M., Charman S.C., Wallwork J., Parameshwar J., and Large S.R. Early mortality after cardiac transplantation: should we do better?. J Heart Lung Transplant 24 (2005) 401-405
21. Morelli A., Teboul J.L., Maggiore S.M., et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 34 (2006) 2287-2293
22. Guarracino F., Cariello C., Danella A., et al. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand 51 (2007) 1217-1224
23. Archan S., and Toller W. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 21 (2008) 78-84
24. Taylor D.O., Edwards L.B., Aurora P., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 27 (2008) 943-956
25. Kavarana M.N., Sinha P., Naka Y., Oz M.C., and Edwards N.M. Mechanical support for the failing cardiac allograft: a single-center experience. J Heart Lung Transplant 22 (2003) 542-547
26. Lima B., Rajagopal K., Petersen R.P., et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation 114 (2006) I27-I32